Evidence map›Paper›PMID 39049720›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Primary and Orthotopic Murine Models of Nasopharyngeal Carcinoma Reveal Molecular Mechanisms Underlying its Malignant Progression.

Xudong Wan, Yuantao Liu, Yiman Peng, Jian Wang, Shu-Mei Yan, Lu Zhang, Wanchun Wu, Lei Zhao, Xuelan Chen, Kexin Ren and 21 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Xudong WanDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Yuantao LiuState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Yiman PengDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Jian WangDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Shu-Mei YanState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Lu ZhangDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Wanchun WuDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Lei ZhaoDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Xuelan ChenDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Kexin RenDepartment of Otolaryngology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Haicheng LongDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Yiling LuoState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Qin YanState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Lele ZhangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Dengzhi LeiDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Pengpeng LiuDepartment of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Shujun LiDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Lihui LiuDepartment of Otolaryngology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Linjie GuoDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Jiajia DuDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Mengsha ZhangDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Siqi DaiDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Yi YangDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Hongyu LiuDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Nianyong ChenDepartment of Otolaryngology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Jinxin BeiState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Lin FengState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Yu LiuDepartment of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.ORCID 0000-0002-1193-7830
Mu-Sheng ZengState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Chong ChenDivision of Thoracic Tumor Multimodality Treatment, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.ORCID 0000-0002-6787-0495
Qian ZhongState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.

Funding

Basic Research Projects of Qinghai Provincial Department of Science and Technology 2023-ZJ-791Frontiers Medical Center, Tianfu Jincheng Laboratory TFJC2023010004Guangdong Science and Technology Department 2020B1212030004National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University Z2024JC001National Key R&D Program 2022YFC3400900National Natural Science Foundation of China 81830090National Natural Science Foundation of China 81874130National Natural Science Foundation of China 82000205National Natural Science Foundation of China 82130007National Natural Science Foundation of China 82170171National Natural Science Foundation of China 82330087National Natural Science Foundation of China T2221004National Natural Science Foundation of China U22A20322Program for Guangdong Introducing Innovative and Enterpreneurial Teams 2019BT02Y198Sichuan Science and Technology Program 2023ZYD0057Sun Yat-sen University Talent Program 22YKLJ08The 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University ZYGD22012The 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University ZYJC21003
6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC), a squamous cell carcinoma originating in the nasopharynx, is a leading malignancy in south China and other south and east Asia areas. It is frequently associated with Epstein-Barr virus (EBV) infection, while there are also some NPC patients without EBV infection. Here, it is shown that the EBV+ (EBV positive) and EBV- (EBV negative) NPCs contain both shared and distinct genetic abnormalities, among the latter are increased mutations in TP53. To investigate the functional roles of NPC-associated genetic alterations, primary, orthotopic, and genetically defined NPC models were developed in mice, a key tool missed in the field. These models, initiated with gene-edited organoids of normal nasopharyngeal epithelium, faithfully recapitulated the pathological features of human disease. With these models, it is found that Trp53 and Cdkn2a deficiency are crucial for NPC initiation and progression. And latent membrane protein1 (LMP1), an EBV-coding oncoprotein, significantly promoted the distal metastasis. Further, loss of TGFBR2, which is frequently disrupted both in EBV- and EBV+ NPCs, dramatically accelerated the progression and lung metastasis of NPC probably by altering tumor microenvironment. Taken together, this work establishes a platform to dissect the genetic mechanisms underlying NPC pathogenesis and might be of value for future translational studies.

Indexed as

Disease Models, AnimalDisease ProgressionNasopharyngeal CarcinomaNasopharyngeal NeoplasmsAnimalsCyclin-Dependent Kinase Inhibitor p16Epstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansMiceReceptor, Transforming Growth Factor-beta Type IITumor Suppressor Protein p53Viral Matrix ProteinsCyclin-Dependent Kinase Inhibitor p16EBV-associated membrane antigen, Epstein-Barr virusReceptor, Transforming Growth Factor-beta Type IITumor Suppressor Protein p53Viral Matrix ProteinsEpstein‐Barr virusmetastasisprimary and orthotopic murine NPC modelsTGFBR2

Identifiers

PMID39049720
PMCPMC11423139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.